Zydus Walks Away From US Dapagliflozin Appeal, ANDA Discontinued
ANDA Sponsor And AstraZeneca Disagreed On Chances Of Settlement
In a blow to potential US generic competition, Zydus Cadila has withdrawn its appeal to an unfavorable federal ruling involving a US Farxiga (dapagliflozin) patent.
